赞诺梅林/化:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|December 23, 2024
概括
赞诺梅林/托斯皮化物 (COBENFYTM) 是一种新的口服药物,已批准用于治疗精神分裂症. 这种药物向特定的大脑受体,以提高疗效,同时减少副作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 精神分裂症的治疗包括向肌酸乙胆受体.
- 克萨诺梅林 (Xanomeline) 是一种肌肉激动剂,显示出有效性,但具有外围副作用.
- 化 (Trospium chloride) 是一种抗体,用于减轻这些副作用.
研究的目的:
- 总结一下xanomeline/trospium chloride的发展里程碑. 总结一下xanomeline/trospium chloride的发展里程碑.
- 为了突出药物的旅程到其第一个监管批准.
主要方法:
- 对临床前和临床发展数据的审查.
- 对监管提交和批准过程的分析.
主要成果:
- 克萨诺梅林/托斯皮化物 (COBENFYTM) 是一种新的口服固剂组合.
- 它作为M1和M4肌肉蛋白受体的激动剂.
- 在2024年9月26日获得美国FDA批准,用于成人精神分裂症.
结论:
- 赞诺梅林/托斯皮化物代表了精神分裂症治疗的重大进展.
- 该组合解决了疗效和耐受性方面的挑战.
- 这项批准标志着一流的肌肉激动剂/对抗剂治疗的关键里程碑.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
Drugs for Treatment of Constipation-Predominant IBS
133
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
133
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
208
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
208
Antidepressant Drugs: MAOIs and Other Agents
194
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
194
Cholinergic Antagonists: Pharmacokinetics
408
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
408
Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K


